Normosang (Human Hemin)

Human Hemin, the active ingredient in Normosang, is a heme preparation presented as a lyophilized powder for solution for injection for intravenous use. It is employed to treat acute hepatic porphyria, including acute intermittent porphyria, hereditary coproporphyria and variegate porphyria, in patients experiencing acute attacks.

GNH USA supplies Normosang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for injectable products. Clients benefit from consistent supply, regulatory support and comprehensive technical assistance.

Normosang is used to manage acute attacks in the porphyria disease family by supplying exogenous heme.

Acute intermittent porphyria: reduces accumulation of neurotoxic porphyrin precursors and alleviates abdominal pain and neurological symptoms. Hereditary coproporphyria: controls acute episodes, decreasing severity of abdominal and neuropsychiatric manifestations. Variegate porphyria: mitigates acute attacks, improving clinical outcomes and reducing hospitalization risk.

Administration of Normosang may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Infusion site pain: discomfort or burning at the injection site. - Nausea: feeling of sickness often occurring during or after infusion. - Headache: mild to moderate head pain reported by some patients. - Fever: transient elevation of body temperature following administration.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response that can include airway compromise. - Hemolysis: rapid destruction of red blood cells leading to anemia. - Renal impairment: decline in kidney function requiring monitoring.

Prior to using Normosang, clinicians should consider several precautionary measures to ensure patient safety. - Dose adjustment in hepatic impairment: reduce dose or monitor closely in patients with liver dysfunction. - Monitor iron status: assess for iron overload during prolonged therapy. - Avoid in known hypersensitivity: do not administer to patients with documented allergy to hemin or formulation components. - Regular laboratory monitoring: check complete blood count and renal function before and during treatment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Normosang can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Barbiturates: may exacerbate porphyria and reduce hemin efficacy. - Sulfonamides: can trigger porphyria attacks when combined with hemin. - Phenytoin: increases risk of neurotoxicity. - Carbamazepine: may worsen porphyria symptoms. - Other heme products: concurrent use can cause iron overload.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may alter heme metabolism; monitor for breakthrough attacks. - Anticoagulants (e.g., warfarin): hemin may affect INR; adjust dose as needed.